Table 2 Outcomes of clinical trials of dual-targeted CAR T-cell immunotherapies in hematological malignancies from ASH 2023
Product | CART19/20 | LV20.19 | C-CAR039 | UCART20 × 22 | CD19/CD70 CAR T-cell therapy | GC012F |
|---|---|---|---|---|---|---|
Disease | r/r B-NHL | r/r MCL | r/r B-NHL | r/r B-NHL | r/r DLBCL | NDMM |
Clinical trial phase | I | I/II | Ib/II | I/IIa | I/II | I |
Targets | CD19/CD20 | CD19/CD20 | CD19/CD20 | CD20/CD22 | CD19/CD70 | BCMA/CD19 |
Dosage | 50 × 106 ± 30% cells 200 × 106 ± 30% cells | 2.5 × 106cells/kg | 1.0–5.0 × 106cells/kg | 50 × 106 cells | NA | 1 × 105 cells/kg 2 × 105 cells/kg 3 × 105 cells/kg |
Patients (n) | 11 | 17 | 48 | 3 | 8 | 22 |
ORR | 90.9% | 100% at day 28 100% at day 90 | 91.5% | 100.0% | 87.5% | 100.0% |
CR | 72.7% | 76% at day 28 92% at day 90 | 85.10% | 66.7% | 75.0% | 95.5% |
mFU (months) | 32.3 | 14 | 23.9 | NA | 19.9 | 13.6 |
Relapse | NA | 2 pts | NA | NA | 3 pts | NA |
Survival | mPFS: NR mOS: NR | PFS: 77% at 1-year OS: 84% at 1-year DOR: 92% at 1-year | PFS: 66.0% at 2-year OS: 77.9% at 2-year | NA | mDFS: 10.5 months mOS: NR | mPFS: NR mDOR: NR |
CRS | 54.50% | 94.1% | 93.80% | 100% | 37.50% | 27.30% |
Grade 1–2 | 54.50% | 94.1% | 91.70% | 100% | 37.50% | 27.30% |
Grade 3–4 | 0% | 0% | 2.10% | 0% | 0% | 0% |
ICANS | 0% | 17.60% | 6.30% | 0% | 0% | 0% |
Grade 1–2 | 0% | 5.90% | 6.30% | 0% | 0% | 0% |
Grade 3–4 | 0% | 11.80% | 0% | 0% | 0% | 0% |
Clinical trial number | NCT04007029 | NCT04186520 | NCT04693676 | NCT05607420 | NCT05436496 | NCT04935580 |
References | [3] | [4] | [5] | [8] | [9] | [11] |